The North America Antimicrobial Resistance Surveillance Market was valued at USD 318.7 Million in 2025 and is expected to reach USD 782.4 Million by 2035, growing at a CAGR of 8.6% from 2024 to 2035. The market is experiencing robust growth owing to rising antimicrobial resistance cases, government initiatives, and the growing need for advanced surveillance systems.
The economic impact of tariffs on "North America Antimicrobial Resistance Surveillance Market".
Market Growth Drivers
Increasing Prevalence of Antimicrobial Resistance: The growing rate of antimicrobial-resistant infections across the US and Canada is a major driver for this market. According to the CDC, over 2.8 million antibiotic-resistant infections occur in the US each year, leading to at least 35,000 deaths. This alarming statistic has pushed both governments and private players, such as Merck & Co., to invest in robust surveillance technologies to monitor, analyze, and combat AMR threats.
Government Funding & Public-Private Partnerships: Regulatory bodies in North America, such as the Public Health Agency of Canada and the Centers for Disease Control and Prevention (CDC), have significantly increased funding for AMR surveillance infrastructure. For example, Thermo Fisher Scientific has collaborated with national laboratories to develop and deploy next-generation sequencing-based surveillance programs, supporting enhanced data collection and response strategies.
Market Trends
Integration of Advanced Data Analytics: Companies like BioMérieux and BD (Becton, Dickinson and Company) are leveraging artificial intelligence and machine learning to improve the efficiency and accuracy of antimicrobial resistance surveillance. These technologies help analyze large-scale datasets, track resistance patterns, and predict outbreaks, enabling timely intervention and resource allocation.
Expansion of Cloud-based Surveillance Platforms: The adoption of cloud-based data platforms for AMR surveillance is gaining momentum. Cerner Corporation, for instance, has launched interoperable cloud solutions enabling real-time sharing of resistance data among hospitals and public health agencies. This enhances collaboration and accelerates the regional response to emerging resistance threats.
Market Opportunities
Expansion into Rural and Underserved Areas: There is significant opportunity for market growth by expanding surveillance infrastructure and solutions to rural and underserved communities in North America. Companies like OpGen are developing portable diagnostic and surveillance tools tailored to these settings.
Personalized Antimicrobial Stewardship Programs: The increasing demand for customized stewardship programs, driven by predictive analytics from surveillance data, presents opportunities for solution providers to collaborate with healthcare systems in offering tailored interventions.
North America Antimicrobial Resistance Surveillance Market Revenue (USD Million), 2020-2035
The chart illustrates the steady rise in market revenue for North America’s antimicrobial resistance surveillance sector from USD 175.2 Million in 2020 to a projected USD 782.4 Million by 2035. Notably, growth accelerates after 2025, as government initiatives and technological advancements drive adoption across healthcare institutions and public health agencies. The market’s expansion is underpinned by growing awareness, investment in digital health solutions, and heightened surveillance needs, resulting in a strong compound annual growth rate (CAGR) of 8.6%.
North America Antimicrobial Resistance Surveillance Market by Region Share (%), 2025
The market share distribution in 2025 shows the United States dominating with 74% share, owing to its advanced healthcare infrastructure and significant government investments. Canada follows with a 19% share, benefiting from national surveillance programs and policy support. Mexico accounts for 5%, reflecting emerging efforts in AMR surveillance. The remaining 2% is split between Bermuda and other North American territories. This regional breakdown highlights the central role of the US while signaling growing market potential in other regions as surveillance adoption spreads.
Recent Developments
In March 2024, the US Centers for Disease Control and Prevention (CDC) announced the expansion of its AR Lab Network to include advanced whole-genome sequencing capacities in key regional laboratories. This move aims to enhance real-time AMR pattern detection, providing actionable data to hospitals and public health authorities.
In April 2024, Thermo Fisher Scientific launched the 'AMR Alert' surveillance software platform specifically for North American hospital networks. The tool integrates with existing laboratory systems, providing automated reporting and analytics to support infection control and stewardship programs.
In February 2024, BD (Becton, Dickinson and Company) partnered with BlueDot, a health data analytics company, to pilot a cloud-based early warning system for outbreak detection of antimicrobial-resistant infections in major North American metropolitan areas. The joint venture underscores the trend toward leveraging AI-powered platforms for regional AMR management.
Press Releases